

Global Tofacitinib Citrate Extended-Release Tablets Market Growth 2024-2030

<https://marketpublishers.com/r/G3CB4786060AEN.html>

Date: November 2024

Pages: 88

Price: US\$ 3,660.00 (Single User License)

ID: G3CB4786060AEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Tofacitinib citrate extended-release tablets refer to a specific pharmaceutical formulation of tofacitinib citrate, a Janus kinase (JAK) inhibitor used in the treatment of certain autoimmune diseases such as rheumatoid arthritis.

The global Tofacitinib Citrate Extended-Release Tablets market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI)'s newest research report, the "Tofacitinib Citrate Extended-Release Tablets Industry Forecast" looks at past sales and reviews total world Tofacitinib Citrate Extended-Release Tablets sales in 2023, providing a comprehensive analysis by region and market sector of projected Tofacitinib Citrate Extended-Release Tablets sales for 2024 through 2030. With Tofacitinib Citrate Extended-Release Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Tofacitinib Citrate Extended-Release Tablets industry.

This Insight Report provides a comprehensive analysis of the global Tofacitinib Citrate Extended-Release Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tofacitinib Citrate Extended-Release Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Tofacitinib Citrate

Extended-Release Tablets market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tofacitinib Citrate Extended-Release Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tofacitinib Citrate Extended-Release Tablets.

United States market for Tofacitinib Citrate Extended-Release Tablets is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Tofacitinib Citrate Extended-Release Tablets is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Tofacitinib Citrate Extended-Release Tablets is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Tofacitinib Citrate Extended-Release Tablets players cover Pfizer, Zydus, Sino Therapeutics, Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Tofacitinib Citrate Extended-Release Tablets market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

11mg per Tablet

22mg per Tablet

Segmentation by Application:

Rheumatoid Arthritis

Psoriatic Arthritis

Ankylosing Spondylitis

Ulcerative Colitis

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Pfizer

Zydus

Sino Therapeutics

Qilu Pharmaceutical

CSPC Ouyi Pharmaceutical

Yichang Humanwell Pharmaceutical

Sichuan Kelun Pharmaceutical

Lepu Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Tofacitinib Citrate Extended-Release Tablets market?

What factors are driving Tofacitinib Citrate Extended-Release Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Tofacitinib Citrate Extended-Release Tablets market opportunities vary by end market size?

How does Tofacitinib Citrate Extended-Release Tablets break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Tofacitinib Citrate Extended-Release Tablets Annual Sales 2019-2030
 - 2.1.2 World Current & Future Analysis for Tofacitinib Citrate Extended-Release Tablets by Geographic Region, 2019, 2023 & 2030
 - 2.1.3 World Current & Future Analysis for Tofacitinib Citrate Extended-Release Tablets by Country/Region, 2019, 2023 & 2030
- 2.2 Tofacitinib Citrate Extended-Release Tablets Segment by Type
 - 2.2.1 11mg per Tablet
 - 2.2.2 22mg per Tablet
- 2.3 Tofacitinib Citrate Extended-Release Tablets Sales by Type
 - 2.3.1 Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2019-2024)
 - 2.3.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue and Market Share by Type (2019-2024)
 - 2.3.3 Global Tofacitinib Citrate Extended-Release Tablets Sale Price by Type (2019-2024)
- 2.4 Tofacitinib Citrate Extended-Release Tablets Segment by Application
 - 2.4.1 Rheumatoid Arthritis
 - 2.4.2 Psoriatic Arthritis
 - 2.4.3 Ankylosing Spondylitis
 - 2.4.4 Ulcerative Colitis
 - 2.4.5 Other
- 2.5 Tofacitinib Citrate Extended-Release Tablets Sales by Application
 - 2.5.1 Global Tofacitinib Citrate Extended-Release Tablets Sale Market Share by

Application (2019-2024)

2.5.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue and Market Share by Application (2019-2024)

2.5.3 Global Tofacitinib Citrate Extended-Release Tablets Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Tofacitinib Citrate Extended-Release Tablets Breakdown Data by Company

3.1.1 Global Tofacitinib Citrate Extended-Release Tablets Annual Sales by Company (2019-2024)

3.1.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Company (2019-2024)

3.2 Global Tofacitinib Citrate Extended-Release Tablets Annual Revenue by Company (2019-2024)

3.2.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Company (2019-2024)

3.2.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Company (2019-2024)

3.3 Global Tofacitinib Citrate Extended-Release Tablets Sale Price by Company

3.4 Key Manufacturers Tofacitinib Citrate Extended-Release Tablets Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Tofacitinib Citrate Extended-Release Tablets Product Location Distribution

3.4.2 Players Tofacitinib Citrate Extended-Release Tablets Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS BY GEOGRAPHIC REGION

4.1 World Historic Tofacitinib Citrate Extended-Release Tablets Market Size by Geographic Region (2019-2024)

4.1.1 Global Tofacitinib Citrate Extended-Release Tablets Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Tofacitinib Citrate Extended-Release Tablets Annual Revenue by

Geographic Region (2019-2024)

4.2 World Historic Tofacitinib Citrate Extended-Release Tablets Market Size by Country/Region (2019-2024)

4.2.1 Global Tofacitinib Citrate Extended-Release Tablets Annual Sales by Country/Region (2019-2024)

4.2.2 Global Tofacitinib Citrate Extended-Release Tablets Annual Revenue by Country/Region (2019-2024)

4.3 Americas Tofacitinib Citrate Extended-Release Tablets Sales Growth

4.4 APAC Tofacitinib Citrate Extended-Release Tablets Sales Growth

4.5 Europe Tofacitinib Citrate Extended-Release Tablets Sales Growth

4.6 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Sales Growth

5 AMERICAS

5.1 Americas Tofacitinib Citrate Extended-Release Tablets Sales by Country

5.1.1 Americas Tofacitinib Citrate Extended-Release Tablets Sales by Country (2019-2024)

5.1.2 Americas Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2019-2024)

5.2 Americas Tofacitinib Citrate Extended-Release Tablets Sales by Type (2019-2024)

5.3 Americas Tofacitinib Citrate Extended-Release Tablets Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Tofacitinib Citrate Extended-Release Tablets Sales by Region

6.1.1 APAC Tofacitinib Citrate Extended-Release Tablets Sales by Region (2019-2024)

6.1.2 APAC Tofacitinib Citrate Extended-Release Tablets Revenue by Region (2019-2024)

6.2 APAC Tofacitinib Citrate Extended-Release Tablets Sales by Type (2019-2024)

6.3 APAC Tofacitinib Citrate Extended-Release Tablets Sales by Application (2019-2024)

6.4 China

6.5 Japan

- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Tofacitinib Citrate Extended-Release Tablets by Country
 - 7.1.1 Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2019-2024)
 - 7.1.2 Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2019-2024)
- 7.2 Europe Tofacitinib Citrate Extended-Release Tablets Sales by Type (2019-2024)
- 7.3 Europe Tofacitinib Citrate Extended-Release Tablets Sales by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets by Country
 - 8.1.1 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Sales by Country (2019-2024)
 - 8.1.2 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2019-2024)
- 8.2 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Sales by Type (2019-2024)
- 8.3 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Sales by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Tofacitinib Citrate Extended-Release Tablets

10.3 Manufacturing Process Analysis of Tofacitinib Citrate Extended-Release Tablets

10.4 Industry Chain Structure of Tofacitinib Citrate Extended-Release Tablets

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Tofacitinib Citrate Extended-Release Tablets Distributors

11.3 Tofacitinib Citrate Extended-Release Tablets Customer

12 WORLD FORECAST REVIEW FOR TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS BY GEOGRAPHIC REGION

12.1 Global Tofacitinib Citrate Extended-Release Tablets Market Size Forecast by Region

12.1.1 Global Tofacitinib Citrate Extended-Release Tablets Forecast by Region (2025-2030)

12.1.2 Global Tofacitinib Citrate Extended-Release Tablets Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country (2025-2030)

12.3 APAC Forecast by Region (2025-2030)

12.4 Europe Forecast by Country (2025-2030)

12.5 Middle East & Africa Forecast by Country (2025-2030)

12.6 Global Tofacitinib Citrate Extended-Release Tablets Forecast by Type (2025-2030)

12.7 Global Tofacitinib Citrate Extended-Release Tablets Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

13.1 Pfizer

13.1.1 Pfizer Company Information

13.1.2 Pfizer Tofacitinib Citrate Extended-Release Tablets Product Portfolios and Specifications

13.1.3 Pfizer Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Pfizer Main Business Overview

13.1.5 Pfizer Latest Developments

13.2 Zydus

13.2.1 Zydus Company Information

13.2.2 Zydus Tofacitinib Citrate Extended-Release Tablets Product Portfolios and Specifications

13.2.3 Zydus Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 Zydus Main Business Overview

13.2.5 Zydus Latest Developments

13.3 Sino Therapeutics

13.3.1 Sino Therapeutics Company Information

13.3.2 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Product Portfolios and Specifications

13.3.3 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)

13.3.4 Sino Therapeutics Main Business Overview

13.3.5 Sino Therapeutics Latest Developments

13.4 Qilu Pharmaceutical

13.4.1 Qilu Pharmaceutical Company Information

13.4.2 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolios and Specifications

13.4.3 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)

13.4.4 Qilu Pharmaceutical Main Business Overview

13.4.5 Qilu Pharmaceutical Latest Developments

13.5 CSPC Ouyi Pharmaceutical

13.5.1 CSPC Ouyi Pharmaceutical Company Information

13.5.2 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolios and Specifications

13.5.3 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets

Sales, Revenue, Price and Gross Margin (2019-2024)

13.5.4 CSPC Ouyi Pharmaceutical Main Business Overview

13.5.5 CSPC Ouyi Pharmaceutical Latest Developments

13.6 Yichang Humanwell Pharmaceutical

13.6.1 Yichang Humanwell Pharmaceutical Company Information

13.6.2 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolios and Specifications

13.6.3 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 Yichang Humanwell Pharmaceutical Main Business Overview

13.6.5 Yichang Humanwell Pharmaceutical Latest Developments

13.7 Sichuan Kelun Pharmaceutical

13.7.1 Sichuan Kelun Pharmaceutical Company Information

13.7.2 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolios and Specifications

13.7.3 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)

13.7.4 Sichuan Kelun Pharmaceutical Main Business Overview

13.7.5 Sichuan Kelun Pharmaceutical Latest Developments

13.8 Lepu Pharmaceutical

13.8.1 Lepu Pharmaceutical Company Information

13.8.2 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolios and Specifications

13.8.3 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2019-2024)

13.8.4 Lepu Pharmaceutical Main Business Overview

13.8.5 Lepu Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. Tofacitinib Citrate Extended-Release Tablets Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Tofacitinib Citrate Extended-Release Tablets Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of 11mg per Tablet

Table 4. Major Players of 22mg per Tablet

Table 5. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales byType (2019-2024) & (K Units)

Table 6. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales Market Share byType (2019-2024)

Table 7. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue byType (2019-2024) & (\$ million)

Table 8. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue Market Share byType (2019-2024)

Table 9. GlobalTofacitinib Citrate Extended-ReleaseTablets Sale Price byType (2019-2024) & (US\$/Unit)

Table 10. GlobalTofacitinib Citrate Extended-ReleaseTablets Sale by Application (2019-2024) & (K Units)

Table 11. GlobalTofacitinib Citrate Extended-ReleaseTablets Sale Market Share by Application (2019-2024)

Table 12. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue by Application (2019-2024) & (\$ million)

Table 13. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue Market Share by Application (2019-2024)

Table 14. GlobalTofacitinib Citrate Extended-ReleaseTablets Sale Price by Application (2019-2024) & (US\$/Unit)

Table 15. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales by Company (2019-2024) & (K Units)

Table 16. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Company (2019-2024)

Table 17. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue by Company (2019-2024) & (\$ millions)

Table 18. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue Market Share by Company (2019-2024)

Table 19. GlobalTofacitinib Citrate Extended-ReleaseTablets Sale Price by Company (2019-2024) & (US\$/Unit)

Table 20. Key ManufacturersTofacitinib Citrate Extended-ReleaseTablets Producing Area Distribution and Sales Area

Table 21. PlayersTofacitinib Citrate Extended-ReleaseTablets Products Offered

Table 22.Tofacitinib Citrate Extended-ReleaseTablets Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales by Geographic Region (2019-2024) & (K Units)

Table 26. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales Market Share Geographic Region (2019-2024)

Table 27. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 28. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue Market Share by Geographic Region (2019-2024)

Table 29. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales by Country/Region (2019-2024) & (K Units)

Table 30. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Country/Region (2019-2024)

Table 31. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue by Country/Region (2019-2024) & (\$ millions)

Table 32. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue Market Share by Country/Region (2019-2024)

Table 33. AmericasTofacitinib Citrate Extended-ReleaseTablets Sales by Country (2019-2024) & (K Units)

Table 34. AmericasTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Country (2019-2024)

Table 35. AmericasTofacitinib Citrate Extended-ReleaseTablets Revenue by Country (2019-2024) & (\$ millions)

Table 36. AmericasTofacitinib Citrate Extended-ReleaseTablets Sales byType (2019-2024) & (K Units)

Table 37. AmericasTofacitinib Citrate Extended-ReleaseTablets Sales by Application (2019-2024) & (K Units)

Table 38. APACTofacitinib Citrate Extended-ReleaseTablets Sales by Region (2019-2024) & (K Units)

Table 39. APACTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Region (2019-2024)

Table 40. APACTofacitinib Citrate Extended-ReleaseTablets Revenue by Region (2019-2024) & (\$ millions)

Table 41. APACTofacitinib Citrate Extended-ReleaseTablets Sales byType (2019-2024) & (K Units)

Table 42. APACTofacitinib Citrate Extended-ReleaseTablets Sales by Application (2019-2024) & (K Units)

Table 43. EuropeTofacitinib Citrate Extended-ReleaseTablets Sales by Country (2019-2024) & (K Units)

Table 44. EuropeTofacitinib Citrate Extended-ReleaseTablets Revenue by Country (2019-2024) & (\$ millions)

Table 45. EuropeTofacitinib Citrate Extended-ReleaseTablets Sales byType

(2019-2024) & (K Units)

Table 46. EuropeTofacitinib Citrate Extended-ReleaseTablets Sales by Application
(2019-2024) & (K Units)

Table 47. Middle East & AfricaTofacitinib Citrate Extended-ReleaseTablets Sales by
Country (2019-2024) & (K Units)

Table 48. Middle East & AfricaTofacitinib Citrate Extended-ReleaseTablets Revenue
Market Share by Country (2019-2024)

Table 49. Middle East & AfricaTofacitinib Citrate Extended-ReleaseTablets Sales
byType (2019-2024) & (K Units)

Table 50. Middle East & AfricaTofacitinib Citrate Extended-ReleaseTablets Sales by
Application (2019-2024) & (K Units)

Table 51. Key Market Drivers & Growth Opportunities ofTofacitinib Citrate Extended-
ReleaseTablets

Table 52. Key Market Challenges & Risks ofTofacitinib Citrate Extended-
ReleaseTablets

Table 53. Key IndustryTrends ofTofacitinib Citrate Extended-ReleaseTablets

Table 54.Tofacitinib Citrate Extended-ReleaseTablets Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56.Tofacitinib Citrate Extended-ReleaseTablets Distributors List

Table 57.Tofacitinib Citrate Extended-ReleaseTablets Customer List

Table 58. GlobalTofacitinib Citrate Extended-ReleaseTablets SalesForecast by Region
(2025-2030) & (K Units)

Table 59. GlobalTofacitinib Citrate Extended-ReleaseTablets RevenueForecast by
Region (2025-2030) & (\$ millions)

Table 60. AmericasTofacitinib Citrate Extended-ReleaseTablets SalesForecast by
Country (2025-2030) & (K Units)

Table 61. AmericasTofacitinib Citrate Extended-ReleaseTablets Annual
RevenueForecast by Country (2025-2030) & (\$ millions)

Table 62. APACTofacitinib Citrate Extended-ReleaseTablets SalesForecast by Region
(2025-2030) & (K Units)

Table 63. APACTofacitinib Citrate Extended-ReleaseTablets Annual RevenueForecast
by Region (2025-2030) & (\$ millions)

Table 64. EuropeTofacitinib Citrate Extended-ReleaseTablets SalesForecast by
Country (2025-2030) & (K Units)

Table 65. EuropeTofacitinib Citrate Extended-ReleaseTablets RevenueForecast by
Country (2025-2030) & (\$ millions)

Table 66. Middle East & AfricaTofacitinib Citrate Extended-ReleaseTablets
SalesForecast by Country (2025-2030) & (K Units)

Table 67. Middle East & AfricaTofacitinib Citrate Extended-ReleaseTablets

RevenueForecast by Country (2025-2030) & (\$ millions)

Table 68. GlobalTofacitinib Citrate Extended-ReleaseTablets SalesForecast byType (2025-2030) & (K Units)

Table 69. GlobalTofacitinib Citrate Extended-ReleaseTablets RevenueForecast byType (2025-2030) & (\$ millions)

Table 70. GlobalTofacitinib Citrate Extended-ReleaseTablets SalesForecast by Application (2025-2030) & (K Units)

Table 71. GlobalTofacitinib Citrate Extended-ReleaseTablets RevenueForecast by Application (2025-2030) & (\$ millions)

Table 72. Pfizer Basic Information,Tofacitinib Citrate Extended-ReleaseTablets Manufacturing Base, Sales Area and Its Competitors

Table 73. PfizerTofacitinib Citrate Extended-ReleaseTablets Product Portfolios and Specifications

Table 74. PfizerTofacitinib Citrate Extended-ReleaseTablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 75. Pfizer Main Business

Table 76. Pfizer Latest Developments

Table 77. Zydus Basic Information,Tofacitinib Citrate Extended-ReleaseTablets Manufacturing Base, Sales Area and Its Competitors

Table 78. ZydusTofacitinib Citrate Extended-ReleaseTablets Product Portfolios and Specifications

Table 79. ZydusTofacitinib Citrate Extended-ReleaseTablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 80. Zydus Main Business

Table 81. Zydus Latest Developments

Table 82. SinoTherapeutics Basic Information,Tofacitinib Citrate Extended-ReleaseTablets Manufacturing Base, Sales Area and Its Competitors

Table 83. SinoTherapeuticsTofacitinib Citrate Extended-ReleaseTablets Product Portfolios and Specifications

Table 84. SinoTherapeuticsTofacitinib Citrate Extended-ReleaseTablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 85. SinoTherapeutics Main Business

Table 86. SinoTherapeutics Latest Developments

Table 87. Qilu Pharmaceutical Basic Information,Tofacitinib Citrate Extended-ReleaseTablets Manufacturing Base, Sales Area and Its Competitors

Table 88. Qilu PharmaceuticalTofacitinib Citrate Extended-ReleaseTablets Product Portfolios and Specifications

Table 89. Qilu PharmaceuticalTofacitinib Citrate Extended-ReleaseTablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 90. Qilu Pharmaceutical Main Business
Table 91. Qilu Pharmaceutical Latest Developments
Table 92. CSPC Ouyi Pharmaceutical Basic Information,Tofacitinib Citrate Extended-ReleaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 93. CSPC Ouyi PharmaceuticalTofacitinib Citrate Extended-ReleaseTablets Product Portfolios and Specifications
Table 94. CSPC Ouyi PharmaceuticalTofacitinib Citrate Extended-ReleaseTablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
Table 95. CSPC Ouyi Pharmaceutical Main Business
Table 96. CSPC Ouyi Pharmaceutical Latest Developments
Table 97. Yichang Humanwell Pharmaceutical Basic Information,Tofacitinib Citrate Extended-ReleaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 98. Yichang Humanwell PharmaceuticalTofacitinib Citrate Extended-ReleaseTablets Product Portfolios and Specifications
Table 99. Yichang Humanwell PharmaceuticalTofacitinib Citrate Extended-ReleaseTablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
Table 100. Yichang Humanwell Pharmaceutical Main Business
Table 101. Yichang Humanwell Pharmaceutical Latest Developments
Table 102. Sichuan Kelun Pharmaceutical Basic Information,Tofacitinib Citrate Extended-ReleaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 103. Sichuan Kelun PharmaceuticalTofacitinib Citrate Extended-ReleaseTablets Product Portfolios and Specifications
Table 104. Sichuan Kelun PharmaceuticalTofacitinib Citrate Extended-ReleaseTablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
Table 105. Sichuan Kelun Pharmaceutical Main Business
Table 106. Sichuan Kelun Pharmaceutical Latest Developments
Table 107. Lepu Pharmaceutical Basic Information,Tofacitinib Citrate Extended-ReleaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 108. Lepu PharmaceuticalTofacitinib Citrate Extended-ReleaseTablets Product Portfolios and Specifications
Table 109. Lepu PharmaceuticalTofacitinib Citrate Extended-ReleaseTablets Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
Table 110. Lepu Pharmaceutical Main Business
Table 111. Lepu Pharmaceutical Latest Developments

LIST OFFIGURES

Figure 1. Picture of Tofacitinib Citrate Extended-Release Tablets

Figure 2. Tofacitinib Citrate Extended-Release Tablets Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Tofacitinib Citrate Extended-Release Tablets Sales Growth Rate 2019-2030 (K Units)

Figure 7. Global Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate 2019-2030 (\$ millions)

Figure 8. Tofacitinib Citrate Extended-Release Tablets Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Figure 9. Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country/Region (2023)

Figure 10. Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country/Region (2019, 2023 & 2030)

Figure 11. Product Picture of 11mg per Tablet

Figure 12. Product Picture of 22mg per Tablet

Figure 13. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type in 2023

Figure 14. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2019-2024)

Figure 15. Tofacitinib Citrate Extended-Release Tablets Consumed in Rheumatoid Arthritis

Figure 16. Global Tofacitinib Citrate Extended-Release Tablets Market: Rheumatoid Arthritis (2019-2024) & (K Units)

Figure 17. Tofacitinib Citrate Extended-Release Tablets Consumed in Psoriatic Arthritis

Figure 18. Global Tofacitinib Citrate Extended-Release Tablets Market: Psoriatic Arthritis (2019-2024) & (K Units)

Figure 19. Tofacitinib Citrate Extended-Release Tablets Consumed in Ankylosing Spondylitis

Figure 20. Global Tofacitinib Citrate Extended-Release Tablets Market: Ankylosing Spondylitis (2019-2024) & (K Units)

Figure 21. Tofacitinib Citrate Extended-Release Tablets Consumed in Ulcerative Colitis

Figure 22. Global Tofacitinib Citrate Extended-Release Tablets Market: Ulcerative Colitis (2019-2024) & (K Units)

Figure 23. Tofacitinib Citrate Extended-Release Tablets Consumed in Other

Figure 24. Global Tofacitinib Citrate Extended-Release Tablets Market: Other (2019-2024) & (K Units)

Figure 25. GlobalTofacitinib Citrate Extended-ReleaseTablets Sale Market Share by Application (2023)

Figure 26. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue Market Share by Application in 2023

Figure 27.Tofacitinib Citrate Extended-ReleaseTablets Sales by Company in 2023 (K Units)

Figure 28. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Company in 2023

Figure 29.Tofacitinib Citrate Extended-ReleaseTablets Revenue by Company in 2023 (\$ millions)

Figure 30. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue Market Share by Company in 2023

Figure 31. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Geographic Region (2019-2024)

Figure 32. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue Market Share by Geographic Region in 2023

Figure 33. AmericasTofacitinib Citrate Extended-ReleaseTablets Sales 2019-2024 (K Units)

Figure 34. AmericasTofacitinib Citrate Extended-ReleaseTablets Revenue 2019-2024 (\$ millions)

Figure 35. APACTofacitinib Citrate Extended-ReleaseTablets Sales 2019-2024 (K Units)

Figure 36. APACTofacitinib Citrate Extended-ReleaseTablets Revenue 2019-2024 (\$ millions)

Figure 37. EuropeTofacitinib Citrate Extended-ReleaseTablets Sales 2019-2024 (K Units)

Figure 38. EuropeTofacitinib Citrate Extended-ReleaseTablets Revenue 2019-2024 (\$ millions)

Figure 39. Middle East & AfricaTofacitinib Citrate Extended-ReleaseTablets Sales 2019-2024 (K Units)

Figure 40. Middle East & AfricaTofacitinib Citrate Extended-ReleaseTablets Revenue 2019-2024 (\$ millions)

Figure 41. AmericasTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Country in 2023

Figure 42. AmericasTofacitinib Citrate Extended-ReleaseTablets Revenue Market Share by Country (2019-2024)

Figure 43. AmericasTofacitinib Citrate Extended-ReleaseTablets Sales Market Share byType (2019-2024)

Figure 44. AmericasTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by

Application (2019-2024)

Figure 45. United StatesTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 46. CanadaTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 47. MexicoTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 48. BrazilTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 49. APACTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Region in 2023

Figure 50. APACTofacitinib Citrate Extended-ReleaseTablets Revenue Market Share by Region (2019-2024)

Figure 51. APACTofacitinib Citrate Extended-ReleaseTablets Sales Market Share byType (2019-2024)

Figure 52. APACTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Application (2019-2024)

Figure 53. ChinaTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 54. JapanTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 55. South KoreaTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 56. Southeast AsiaTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 57. IndiaTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 58. AustraliaTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 59. ChinaTaiwanTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 60. EuropeTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Country in 2023

Figure 61. EuropeTofacitinib Citrate Extended-ReleaseTablets Revenue Market Share by Country (2019-2024)

Figure 62. EuropeTofacitinib Citrate Extended-ReleaseTablets Sales Market Share byType (2019-2024)

Figure 63. EuropeTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Application (2019-2024)

Figure 64. GermanyTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 65.FranceTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 66. UKTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 67. ItalyTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 68. RussiaTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 69. Middle East & AfricaTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Country (2019-2024)

Figure 70. Middle East & AfricaTofacitinib Citrate Extended-ReleaseTablets Sales Market Share byType (2019-2024)

Figure 71. Middle East & AfricaTofacitinib Citrate Extended-ReleaseTablets Sales Market Share by Application (2019-2024)

Figure 72. EgyptTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 73. South AfricaTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 74. IsraelTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 75.TurkeyTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 76. GCC CountriesTofacitinib Citrate Extended-ReleaseTablets Revenue Growth 2019-2024 (\$ millions)

Figure 77. Manufacturing Cost Structure Analysis ofTofacitinib Citrate Extended-ReleaseTablets in 2023

Figure 78. Manufacturing Process Analysis ofTofacitinib Citrate Extended-ReleaseTablets

Figure 79. Industry Chain Structure ofTofacitinib Citrate Extended-ReleaseTablets

Figure 80. Channels of Distribution

Figure 81. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales MarketForecast by Region (2025-2030)

Figure 82. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue Market ShareForecast by Region (2025-2030)

Figure 83. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales Market ShareForecast byType (2025-2030)

Figure 84. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue Market

ShareForecast byType (2025-2030)

Figure 85. GlobalTofacitinib Citrate Extended-ReleaseTablets Sales Market

ShareForecast by Application (2025-2030)

Figure 86. GlobalTofacitinib Citrate Extended-ReleaseTablets Revenue Market

ShareForecast by Application (2025-2030)

I would like to order

Product name: Global Tofacitinib Citrate Extended-Release Tablets Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/G3CB4786060AEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3CB4786060AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970